OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Metabolism is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art	700
Metabolic-associated fatty liver disease and lipoprotein metabolism	266
Dysregulated lipid metabolism links NAFLD to cardiovascular disease	265
GLP-1 physiology informs the pharmacotherapy of obesity	180
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans	178
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease	171
A guide to understanding endoplasmic reticulum stress in metabolic disorders	169
Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street	154
Role of NAD+ in regulating cellular and metabolic signaling pathways	149
The melanocortin pathway and energy homeostasis: From discovery to obesity therapy	132
Insulin-like growth factors: Ligands, binding proteins, and receptors	128
Insulin action at a molecular level – 100 years of progress	123
Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD	122
Hepatokines and metabolism: Deciphering communication from the liver	120
Imaging biomarkers of NAFLD, NASH, and fibrosis	112
Metabolic drivers of non-alcoholic fatty liver disease	110
The brain as an insulin-sensitive metabolic organ	101
Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis	96
Genetic and epigenetic factors determining NAFLD risk	88
CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing	87
GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease	79
Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis	75
Single-cell transcriptomics of human islet ontogeny defines the molecular basis of β-cell dedifferentiation in T2D	74
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms	73
Ferroptosis and ferritinophagy in diabetes complications	73

Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation	71
Understanding insulin and its receptor from their three-dimensional structures	68
Overexpression of the vitamin D receptor (VDR) induces skeletal muscle hypertrophy	66
Chronic inflammation and the hallmarks of aging	64
Exploring the therapeutic potential of mitochondrial uncouplers in cancer	64
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice	63
Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment	63
Wnt/β-catenin signaling regulates adipose tissue lipogenesis and adipocyte-specific loss is rigorously defended by neighboring stromal-vascular cells	62
Mitochondrial oxidative function in NAFLD: Friend or foe?	61
Infusion of donor feces affects the gut–brain axis in humans with metabolic syndrome	59
Role and mechanism of ferroptosis in neurological diseases	58
Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload	56
Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH	56
Impacts of essential amino acids on energy balance	54
FGF19 and FGF21: In NASH we trust	51
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy	51
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists	49
Sperm histone H3 lysine 4 tri-methylation serves as a metabolic sensor of paternal obesity and is associated with the inheritance of metabolic dysfunction	48
A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing	47
LEAP2 deletion in mice enhances ghrelin's actions as an orexigen and growth hormone secretagogue	46
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction	46